Contrast safety in the cancer patient: preventing contrast-induced nephropathy

AUTOR(ES)

Heiken, Jay P.

FONTE

e-Med

RESUMO

Cancer patients undergo frequent imaging examinations. Computed tomography (CT) examinations for tumor staging and assessment of treatment response generally require administration of intravascular contrast medium. Iodinated contrast agents for CT are associated with the risk of contrast-induced nephrotoxicity (CIN), particularly in patients with impaired renal function and diabetes. In many cancer patients the risk of complications from intravascular contrast medium administration is compounded by advanced age, dehydration and coadministration of nephrotoxic chemotherapeutic drugs. In this article I review the definition, clinical manifestations, possible mechanisms and risk factors for CIN, and provide recommendations for prevention of this potentially life-threatening complication.

Documentos Relacionados

• Trimetazidine in the prevention of contrast‐induced nephropathy after coronary procedures
• Contrast-Induced Nephropathy and Long-Term Adverse Events: Cause and Effect?
• Hyperuricemia may be related to contrast-induced nephropathy after percutaneous coronary intervention
• Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis
• An experimental study on the preventive effects of N-acetyl cysteine and ozone treatment against contrast-induced nephropathy